Conference Sponsors 2019

Thank you to our event sponsors for their support in delivering the Retina UK Annual Conference 2019.

Novartis

Novartis supports Retina UK through project funding and event sponsorship. Novartis holds the European licence for the first ever commercially available gene therapy for an inherited retinal dystrophy – Luxturna – designed to treat sight loss caused by mutations on the RPE65 gene.

ProQR
Roche